CliffBio
small molecule

PHOSLO

CALCIUM ACETATE

Loss of exclusivity—loss of exclusivity
CompanyFRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC

Drug detail

Brand namePHOSLO
Active ingredientCALCIUM ACETATE
Strength667MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1990
Marketing statusDISCN

More from FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

PHOSLO patent cliff — loss of exclusivity — | CliffBio